Trends in palliative care and life-sustaining procedure provision for patients with cervical cancer in the United States

Objective: This study aimed to identify trends in palliative care (PC) and life-sustaining procedures (LSP) provision and factors related to palliative care provision in patients with cervical cancer in the United States (US). Methods: This serial and cross-sectional study was based on the National Inpatient Sample dataset from 2008 to 2017. The compound annual growth rate (CAGR) was adopted for calculating annual change of PC and LSP. Multivariate logistic regression analyses were used to investigate factors related to PC. Results: The rate of PC consultation in patients with cervical cancer in the US increased steadily from 2.5% in 2008 to 12.8% in 2017 with the CAGR reaching 17.9% (p for trend <0.001). The annual change in the percentage of LSP was not statistically significant in the entire cervical cancer cohort (CAGR = 1.2%, p = 0.623); however, a decreasing tendency was observed over time in the subgroups receiving PC (odds ratio, [95% confidence interval] = 0.95, [0.91–0.99]). Blacks, Hispanics, and Asian/Pacific Islanders were all more likely to receive PC than Caucasians. Patients with Medicaid as the primary payer less frequently received PC consultation than those with Medicare as the primary payer. In addition, the likelihood of undergoing LSPs increased with the severity of the disease. Conclusion: The rate of PC consultation in patients with cervical cancer in the US, although low, is increasing continuously. From a humanitarian perspective, increasing the rate of PC consultation in the treatment trajectory of cervical cancer is important.

Palliative care; Uterine cervical neoplasms; Medicaid; National inpatient sample

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020; 70: 7–30.

[2] Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. Journal of the National Cancer Institute. 2017; 109: djx030.

[3] Campos NG, Tsu V, Jeronimo J, Mvundura M, Kim JJ. Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings. Cancer Medicine. 2017; 6: 2008–2014.

[4] Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015; 385: 977–1010.

[5] Datta GD, Colditz GA, Kawachi I, Subramanian SV, Palmer JR, Rosenberg L. Individual-, neighborhood-, and state-level socioeconomic predictors of cervical carcinoma screening among U.S. black women: a multilevel analysis. Cancer. 2006; 106: 664–669.

[6] Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the Cervix Uteri. International Journal of Gynaecology and Obstetrics. 2019; 95: S43–S103.

[7] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021; 71: 7–33.

[8] Hong J, Tsai C, Lai C, Chang T, Wang C, Chou H, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2004; 60: 249–257.

[9] National Comprehensive Cancer Network. Cervical cancer (Ver- sion 2.2020). Available at: https://www.nccn.org/guidelines/guid elines-detail?category=1&id=1426 (Accessed: 5 August 2020).

[10] Wachterman MW, Pilver C, Smith D, Ersek M, Lipsitz SR, Keating NL. Quality of End-of-Life Care Provided to Patients with Different Serious Illnesses. JAMA Internal Medicine. 2016; 176: 1095–1102.

[11] Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jack- son VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. The New England Journal of Medicine. 2010; 363: 733–742.

[12] Ma J, Chi S, Buettner B, Pollard K, Muir M, Kolekar C, et al. Early Palliative Care Consultation in the Medical ICU: A Cluster Ran- domized Crossover Trial. Critical Care Medicine. 2019; 47: 1707– 1715.

[13] Gaertner J, Wolf J, Ostgathe C, Toepelt K, Glossmann J, Hallek M, et al. Specifying who recommendation: moving toward disease-specific guidelines. Journal of Palliative Medicine. 2010; 13: 1273– 1276.

[14] Rogers M, Meier DE, Morrison RS, Moreno J, Aldridge M. Hospital Characteristics Associated with Palliative Care Program Prevalence. Journal of Palliative Medicine. 2020; 23: 1296–1299.

[15] Chiu TY, Hu WY, Cheng SY, Chen CY. Ethical dilemmas in palliative care: a study in Taiwan. J Med Ethics. 2000; 26: 353–357.

[16] Wood J, Smith C. End-of-life care: preparing patients and fami- lies. Nature Reviews Urology. 2010; 7: 425–429.

[17] Landrum LM, Blank S, Chen L, Duska L, Bae-Jump V, Lee PS, et al. Comprehensive care in gynecologic oncology: the importance of palliative care. Gynecologic Oncology. 2015; 137: 193–202.

[18] Healthcare Cost and Utilization Project (HCUP). HCUP NIS Database Documentation. Agency for Healthcare Research and Quality, Rockville, MD. 2016. Available at: https://www.hcupus.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp (Accessed: 18 April 2019).

[19] World Health Organization. WHO Definition of Palliative Care. 2020. Available at: https://www.who.int/news-room/fact-sheet s/detail/palliative-care (Accessed: 5 August 2020).

[20] Lopez-Acevedo M, Lowery WJ, Lowery AW, Lee PS, Havrilesky LJ. Palliative and hospice care in gynecologic cancer: a review. Gynecologic Oncology. 2013; 131: 215–221.

[21] Hwang J, Shen J, Kim SJ, Chun S, Kioka M, Sheraz F, et al. Ten-Year Trends of Utilization of Palliative Care Services and Life-Sustaining Treatments and Hospital Costs Associated with Patients with Terminally Ill Lung Cancer in the United States from 2005 to 2014. American Journal of Hospice and Palliative Medicine. 2019; 36: 1105–1113.

[22] Shen JJ, Ko E, Kim P, Kim SJ, Lee Y, Lee J, et al. Life-Sustaining Procedures, Palliative Care Consultation, and do-not Resuscitate Status in Dying Patients with COPD in us Hospitals: 2010-2014. Journal of Palliative Care. 2018; 33: 159–166.

[23] Lee Y, Yoo JW, Hua L, Kim PC, Kim SJ, Shen JJ. Ten-year trends of palliative care utilization associated with multiple sclerosis patients in the United States from 2005 to 2014. Journal of Clinical Neuroscience. 2018; 58: 13–19.

[24] Yu KG, Shen JJ, Kim PC, Kim SJ, Lee SW, Byun D, et al. Trends of Hospital Palliative Care Utilization and its Associated Factors among Patients with Systemic Lupus Erythematosus in the United States from 2005 to 2014. American Journal of Hospice and Palliative Medicine. 2019; 37: 164–171.

[25] Ibfelt E, Kjær SK, Johansen C, Høgdall C, Steding-Jessen M, Frederiksen K, et al. Socioeconomic position and stage of cervical cancer in Danish women diagnosed 2005 to 2009. Cancer Epidemiol- ogy, Biomarkers & Prevention. 2012; 21: 835–842.

[26] McCarthy AM, Dumanovsky T, Visvanathan K, Kahn AR, Schymura MJ. Racial/ethnic and socioeconomic disparities in mortality among women diagnosed with cervical cancer in New York City, 1995–2006. Cancer Causes & Control. 2010; 21: 1645–1655.

[27] Kish JK, Rolin AI, Zou Z, Cucinelli JE, Tatalovich Z, Saraiya M, et al. Prioritizing us Cervical Cancer Prevention with Results from a Geospatial Model. Journal of Global Oncology. 2016; 2: 275–283.

[28] Kim DJ, Choi MS. Life-sustaining treatment and palliative care in patients with liver cirrhosis - legal, ethical, and practical issues. Clinical and Molecular Hepatology. 2017; 23: 115–122.

[29] Lee E. Dying well in South Korea: Korean hospitals are slowly opening up new avenues for caring for terminal patients-including the right to stop care. THE KOREAS. 2019. Avail- able at: https://thediplomat.com/2019/06/dying-well-in-south-korea (Accessed: 19 June 2019).

[30] Choi Y-H, Hwang S-W, Kim T-H, Park S-M, Kim K-R, Shin W-J, et al. Knowledge, perception of hospice palliative care by terminal cancer patients. Korean Journal of Family Practice. 2015; 5: 58–63.

[31] Kim S, Choi S, Shin SH, Ryu J, Baik J. Development of a Community-Based Palliative Care Model for Advance Cancer Patients in Public Health Centers in Busan, Korea. Cancer Research and Treatment. 2017; 49: 559–568.

[32] Haverhals LM, Manheim CE, Mor V, Ersek M, Kinosian B, Lorenz KA, et al. The experience of providing hospice care concurrent with cancer treatment in the VA. Supportive Care in Cancer. 2019; 27: 1263–1270.

[33] Kaiser U, Vehling-Kaiser U, Kück F, Mechie N, Hoffmann A, Kaiser F. Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis. BMC Palliative Care. 2020; 19: 140.

[34] Casarett DJ, Fishman JM, Lu HL, O’Dwyer PJ, Barg FK, Naylor MD, et al. The terrible choice: re-evaluating hospice eligibility criteria for cancer. Journal of Clinical Oncology. 2009; 27: 953–959.

[35] Starr LT, Ulrich CM, Junker P, Huang L, O’Connor NR, Meghani SH. Patient Risk Factor Profiles Associated with the Timing of Goals-of-Care Consultation before Death: a Classification and Regression Tree Analysis. American Journal of Hospice and Palliative Medicine. 2020; 37: 767–778.

[36] Medicare Payment Advisory Commission. Section 6: Acute inpa- tient services. A Data Book: Health care spending and the Medicare program (pp.55–90 ). Washington, DC. 2020.

[37] Medicare Learning Network. Hospital Value-Based Purchasing Program: Centers for Medicare & Medicaid Services. 2011. Avail- able at: https://www.neebco.com/Hospital_VBPurchasing_Fact_ Sheet_ICN907664.pdf (Accessed: 11 April 2011).

[38] Gauri A, Messiah SE, Bouzoubaa LA, Moore KJ, Koru-Sengul T. Cervical cancer sociodemographic and diagnostic disparities in Florida: a population-based study (1981–2013) by stage at presentation. Ethnicity & Health. 2020; 25: 995–1003.